source
- Epicrispr and Infinimmune secure $165 million in venture funding for epigenetic and antibody programsEpicrispr Biotechnologies announced a $90 million Series C round to push its epigenetic therapy program for facioscapulohumeral muscular dystrophy (FSHD). The lead candidate, EPI-321, is in a firs…
- Medicare’s new $50 GLP‑1 weight‑loss drug program may create barriers for patients, warns expertsMedicare has launched a program that caps out‑of‑pocket costs for GLP‑1 weight‑loss medicines such as Wegovy, Zepbound and Foundayo at $50 a month for eligible beneficiaries. The initiative is inte…